These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17803335)

  • 1. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.
    Heeg BM; Peters RJ; Botteman M; van Hout BA
    Pharmacoeconomics; 2007; 25(9):769-82. PubMed ID: 17803335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials.
    Berg J; Fidan D; Lindgren P
    Curr Med Res Opin; 2008 Jul; 24(7):2089-101. PubMed ID: 18547464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
    Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
    Kolm P; Yuan Y; Veledar E; Mehta SR; O'Brien JA; Weintraub WS
    Can J Cardiol; 2007 Nov; 23(13):1037-42. PubMed ID: 17985004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Schleinitz MD; Heidenreich PA
    Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
    Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
    J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events.
    Weintraub W; Jönsson B; Bertrand M
    Pharmacoeconomics; 2004; 22 Suppl 4():29-41. PubMed ID: 15876010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
    Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
    Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
    JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
    Ringborg A; Lindgren P; Jönsson B
    Eur J Health Econ; 2005 Dec; 6(4):354-6, 358-62. PubMed ID: 16267654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of clopidogrel in the management of acute coronary syndromes.
    Wodlinger AM; Pieper JA
    Clin Ther; 2003 Aug; 25(8):2155-81. PubMed ID: 14512126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
    Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
    Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.